Real-world progression-free survival and overall survival in patients with HR<sup>+</sup>/HER2<sup>-</sup> advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study.

Int J Cancer · 2026 · PMC13139987 · PMID 41792052

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

Consistently, the HRs from the adjusted model for the comparison of ET versus ribociclib (HR = 1.288; 95%‐CI: [1.006; 1.649]) or CT versus ribociclib (HR = 1.776; 95%‐CI: [1.377; 2.290]) were in favor of ribociclib, and the related 95%‐CIs indicated nominally significant differences.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Real-world progression-free survival and overall survival in patients with HR&lt;sup&gt;+&lt;/sup&gt;/HER2&lt;sup&gt;-&lt;/sup&gt; advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study.

The sentences

Real-world progression-free survival and overall survival in patients with HR<sup>+</sup>/HER2<sup>-</sup> advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study.